LONG MINI-FUTURE - GILEAD SCIENCES | Delayed Deutsche Boerse AG 01:42:23 04/06/2024 pm IST | ||
| 1.6 EUR | -0.62% |
|
| Current month | -0.62% | ||
| 1 month | -9.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 04/24/04 | 1.6 | -0.62% |
| 03/24/03 | 1.61 | -0.62% |
| 31/24/31 | 1.62 | -4.71% |
| 30/24/30 | 1.7 | +4.94% |
| 29/24/29 | 1.62 | -2.41% |
Delayed Quote Deutsche Boerse AG
Last update June 04, 2024 at 01:42 pm IST
More quotesStatic data
| Product type | Knock-Out mit Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VP9T2N |
| ISIN | DE000VP9T2N7 |
| Date issued | 29/10/2020 |
| Strike | 46.05 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.29 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.36 € |
|---|---|
| Lowest since issue | 1.12 € |
| Spread | 0.03 € |
| Spread % | 1.84% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.43
USD
Average target price
82.7
USD
Spread / Average Target
+30.38%
- Stock Market
- Certificates
- Certificat
